Anthem Biosciences
Market cap ₹51,526 Cr
- P/E
- 84.51
- Day range
- ₹907.55 – ₹923.70
- 52-week range
- ₹579.15 – ₹989.10
- Volume
- 2.92 L
- Open
- ₹916.20
- Prev close
- ₹924.25
Latest results · Q2 FY27(consolidated)Revenue ₹594 Cr+8.0%Profit ₹211 Cr+21.9%Margin 35.6%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter holding falling
71.40%, down 3.29 pts since 2025-09-30 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
ANTHEM in NSE indices and F&O
Research profile
Composite 64 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.2%
- Graham no.
- ₹119.68
- vs Graham
- -86.9%
- ROE ÷ P/B
- 1.3%
- 12-1 mom.
- +16.6%
- Return / vol
- 1.01
- Magic Formula
- #342
- Piotroski
- 5/6
- FCF yield
- 1.2%
- PEG
- 3.85
Appears in 13 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Anthem BiosciencesANTHEM | ₹51,526 Cr | 84.51 | 16.10 | 21.7% | 30.0% | 46.0% | 0.01 | +8.0% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 3h agoHeadlines about Anthem Biosciences from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 81.6
- Price / Book
- 15.71
- ROE (FY26)
- 21.7%
- ROCE (latest year)
- 30%
- Dividend yield
- 0.22%
Moving averages (NSE)
- 20-day
- ₹876.9
- Price above
- 50-day
- ₹884.41
- Price above
- 200-day
- ₹784.44
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 | 594 |
| YoY Sales growth | — | — | — | — | — | — | -15 | — | -23 | — |
| Expenses | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 | 323 |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 | 271 |
| OPM % | 36% | 37% | 32% | 40% | 35% | 40% | 37% | 44% | 36% | 46% |
| Other Income | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 | 59 |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 | 3 |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 | 31 |
| Profit before tax | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 | 296 |
| Tax % | 30% | 19% | 23% | 54% | 27% | 24% | 29% | 32% | 17% | 29% |
| Net Profit | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 | 211 |
| EPS in Rs | ₹1.47 | ₹2.88 | ₹2.21 | ₹1.47 | ₹2.42 | ₹3.09 | ₹1.65 | ₹3.38 | ₹2.13 | ₹3.75 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+17 days since Mar 2021
+27 days since Mar 2021
-16 days since Mar 2021
+61 days since Mar 2021
+65 days since Mar 2021
Strengths, risks & growth
Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients. [1]
Strengths
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 118 days to 92.3 days
Risks
- Stock is trading at 15.7 times its book value
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +14%
- 3 Years
- +26%
- TTM
- -1%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +17%
- 3 Years
- +21%
- TTM
- +22%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- 1 Year
- +42%
Return on Equity
- 10 Years
- —
- 5 Years
- +23%
- 3 Years
- +21%
- Last Year
- +22%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 74.69% | 74.67% | 71.42% | 71.39% | -0.03 pp |
| FII | 1.37% | 1.28% | 2.57% | 3.79% | +1.22 pp |
| DII | 7.60% | 11.55% | 13.48% | 12.10% | -1.38 pp |
| Public | 16.34% | 12.48% | 12.52% | 12.71% | +0.19 pp |
Filed with NSE for Sept 2026: promoters 71.40%, public 28.60%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 9.25% (-1.90 pp)- Promoters71.4%
- Foreign institutions3.8%
- Mutual funds9.3%
- Insurance1.7%
- Other domestic institutions1.1%
- Retail1.8%
- Others10.9%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Flexi Cap Fund | 1.15% | 0.56% | -0.05 pp |
| SBI Midcap Fund | 0.68% | 1.61% | +0.17 pp |
| Axis Midcap Fund | 0.51% | 0.80% | +0.40 pp |
| Axis ELSS-Tax Saver Fund | 0.46% | 0.80% | +0.07 pp |
| Aditya Birla SL Flexi Cap Fund | 0.39% | 0.72% | +0.01 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 29.3%
- Downside volatility
- 25.6%
- Worst 5% of days
- 2.7%
- Average of that tail
- 3.4%
- Max drawdown (1Y)
- 31.5%
- Below its peak
- 4.6%
Against the market
- Beta vs Nifty 50
- 0.56
- Correlation
- 0.26
- Relative strength (3M)
- -2.1%
- ATR (14)
- 3.0%
Return
- Return 1M
- +11.2%
- Return 3M
- +1.8%
- Return 6M
- +15.9%
- Return 1Y
- +29.7%
- vs 200-day average
- +16.6%
Momentum
- RSI (14)
- 57.6
- MACD histogram
- 6.08
- Stochastic %K
- 56.0
- ADX (14)
- 29.1
- +DI / −DI
- 29.3 / 18.7
- Money flow index
- 67.2
Participation
- Delivery (20d avg)
- 52.1%
- vs its 60-day baseline
- -2.1 pts
- Volume vs 20-day
- -0.4σ
- Close vs day's VWAP
- -0.0%
- 52-week position
- 88 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- ₹633 Cr
- FCF yield
- 1.2%
- Cash conversion
- 1.43
- Accruals ratio
- -0.074
- Net debt
- ₹21 Cr
- Net debt / equity
- 0.01
- EV / sales
- 25.19
- PEG
- 3.85
- Capex intensity
- 9.9%
- Revenue CAGR
- 8.0%
- Profit CAGR
- 21.9%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Viridity Tone LLP Designated Person · Market Sale | Sell | 9,00,000 | ₹82.7 Cr | 21 Sept 2026 |
Viridity Tone LLP Other · Market Sale | Sell | 2,03,13,795 | ₹1255 Cr | 12 Mar 2026 |
Aruna Ganesh Promoter Group · Gift | Buy | 85,57,302 | ₹0 | 12 Mar 2026 |
Krithika Ganesh Promoter Group · Gift | Sell | 85,57,302 | ₹0 | 12 Mar 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹2.00
Dividend - Rs 2 Per Share
25 Jun 2026ex-date
Company announcements
Compliance Certificate under Reg 74(5) of DP Regulations
Intimation of closure of Trading Window for Q2FY27
Intimation of the settlement of Upside Sharing Arrangement
Transcript of Earnings Conference Call held on July 22, 2026.
Anthem Biosciences Limited has submitted the Exchange the voting results and a copy of scrutinizer report of the 20th Annual General Meeting of the Company held on July 22, 2026
Anthem Biosciences Limited has informed the Exchange regarding the Proceedings of the 20th Annual General Meeting held on Wednesday, July 22, 2026
Audio recording of Earnings Call for the quarter ended June 30, 2026.
Newspaper Publication on Unaudited Consolidated and Standalone Financial Results for the quarter ended June 30, 2026
Revised Press Release on Unaudited Financial Results for the quarter ended June 30, 2026
Revised Investor Presentation for Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026
Press Release on Consolidated Financial Results for the quarter ended June 30, 2026
Investor Presentation on Unaudited Consolidated Financial Results for the quarter ended June 30, 2026`
Financials Results for the quarter ended June 30, 2026
Outcome of the Board Meeting held on Tuesday, July 21, 2026
Intimation of Schedule of Earnings Conference Call to discuss on Unaudited Standalone and Consolidated Financial Results for quarter ended June 30, 2026
Filed with BSE (scrip 544449); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Jul 2026TranscriptSlidesRecording
- Jul 2026Slides
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 2 Jul from icra
- Rating update · 20 Jun 2025 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Anthem Biosciences: common questions
Answered from the figures on this page.